×
For best experience we recommend to activate Javascript in your browser.
Recombinant IL33 (Tozorakimab Biosimilar) antibody
This Human Monoclonal antibody specifically detects IL33 (Tozorakimab Biosimilar) in BLI, ELISA, FACS, Func and SPR. It exhibits reactivity toward Human.
Catalog No. ABIN7676108
$346.15
Plus shipping costs $50.00
1 mg ABIN7581510
100 μg ABIN7676108
1 mg ABIN7581510
100 μg ABIN7676108
Delivery in 10 to 12 Business Days
Quick Overview for Recombinant IL33 (Tozorakimab Biosimilar) antibody (ABIN7676108)
Target
IL33 (Tozorakimab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for IL33 (Tozorakimab Biosimilar) antibodies
Human
Clonality
All clonalities for IL33 (Tozorakimab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for IL33 (Tozorakimab Biosimilar) antibodies
This IL33 (Tozorakimab Biosimilar) antibody is un-conjugated
Application
Bio-Layer Interferometry (BLI), ELISA, Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-IL33 (Tozorakimab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-IL-33 Reference Antibody (tozorakimab)
Characteristics
Anti-IL-33 Reference Antibody (tozorakimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for IL33 (Tozorakimab Biosimilar)
(hide)
Target
IL33 (Tozorakimab Biosimilar)
Alternative Name
IL-33 (Tozorakimab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
O95760
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-IL33 (Tozorakimab Biosimilar) antibody (ABIN7676108)
Chat with us , powered by LiveChat